Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). (Q38092174)

28 August 2017

Plasminogen activator inhibitor-1 inhibitors: a patent review (2006-present). (English)

1 reference

28 August 2017

1 reference

Yolanda M Fortenberry

series ordinal

1

1 reference

PubMed ID

23521527

28 August 2017

language of work or name

English

0 references

publication date

25 March 2013

1 reference

Expert Opinion on Therapeutic Patents

28 August 2017

1 reference

28 August 2017

23

1 reference

28 August 2017

801-815

1 reference

28 August 2017

7

1 reference

Colocalization of thrombin, PAI-1, and vitronectin in the atherosclerotic vessel wall: A potential regulatory mechanism of thrombin activity by PAI-1/vitronectin complexes

28 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Molecular basis of renal fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

PAI-1 and kidney fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

PAI-1 - a potential therapeutic target in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

The plasminogen activator inhibitor "paradox" in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

PAI-1 and the metabolic syndrome: links, causes, and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

PAI-1, progress in understanding the clinical problem and its aetiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Lysis of Platelet‐rich Thrombi: The Role of PAI–1a

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Age-dependent spontaneous coronary arterial thrombosis in transgenic mice that express a stable form of human plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Endothelial cells inhibit flow-induced smooth muscle cell migration: role of plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1 and -3 increase cell adhesion and motility of MDA-MB-435 breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor type 1 enhances neointima formation after oxidative vascular injury in atherosclerosis-prone mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: design, synthesis, and preclinical characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

LRP: a multifunctional scavenger and signaling receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Essential role of the low density lipoprotein receptor-related protein in vascular smooth muscle cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1 is an aggregate response factor with pleiotropic effects on cell signaling in vascular disease and the tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Overview of hemostatic factors involved in atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

PAI-1 polymorphisms modulate phenotypes associated with the metabolic syndrome in obese and diabetic Caucasian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

PAI-1 and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1, adipose tissue and insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

The association of inflammatory and fibrinolytic proteins with 5 year change in insulin clearance: the Insulin Resistance Atherosclerosis Study (IRAS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor 1, transforming growth factor-beta1, and BMI are closely associated in human adipose tissue during morbid obesity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Release of PAI-1 by human preadipocytes and adipocytes independent of insulin and IGF-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Regulation of PAI-1 gene expression during adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Metabolic factors, adipose tissue, and plasminogen activator inhibitor-1 levels in type 2 diabetes: findings from the look AHEAD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Prevention of obesity and insulin resistance in mice lacking plasminogen activator inhibitor 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1 in chronic kidney disease: evidence and mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

PAI-1 expression and its regulation by promoter 4G/5G polymorphism in clear cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Type 1 plasminogen activator inhibitor (PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

21 January 2018

PAI-1 in tissue fibrosis

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

PAI-1 deficiency reduces liver fibrosis after bile duct ligation in mice through activation of tPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Hepatic fibrosis, glomerulosclerosis, and a lipodystrophy-like syndrome in PEPCK-TGF-beta1 transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Effect of the small molecule plasminogen activator inhibitor-1 (PAI-1) inhibitor, PAI-749, in clinical models of fibrinolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Novel bis-arylsulfonamides and aryl sulfonimides as inactivators of plasminogen activator inhibitor-1 (PAI-1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Structure-activity relationships of new 2-acylamino-3-thiophenecarboxylic acid dimers as plasminogen activator inhibitor-1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Design, synthesis, and evaluation of orally active inhibitors of plasminogen activator inhibitor-1 (PAI-1) production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Synthesis and evaluation of 1,4-diphenylbutadiene derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Plasminogen activator inhibitor-1 in the aqueous humor of patients with and without glaucoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Emodin upregulates urokinase plasminogen activator, plasminogen activator inhibitor-1 and promotes wound healing in human fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Antimetastatic potential of PAI-1-specific RNA aptamers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

RNA aptamers as reversible antagonists of coagulation factor IXa.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Tissue-specific PAI-1 gene expression and glycosylation pattern in insulin-resistant old rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2013.782393

10.1517/13543776.2013.782393

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23521527